High serum TGF-α predicts poor response to lapatinib and capecitabine in HER2-positive breast cancer

Breast Cancer Research and Treatment

Volumn 125, Issue 1, 2011, Pages 107-114

  Rhee, Jiyoung ^a   Han, Sae Won ^a,b   Cha, Yongjun ^a   Ham, Hye Seon ^b   Kim, Hwang Phill ^b   Oh, Do Youn ^a,b   Im, Seock Ah ^a,b   Park, Jong Wan ^b   Ro, Jungsil ^c   Lee, Keun Seok ^c   Park, In Hae ^c   Im, Young Hyuck ^d   Bang, Yung Jue ^a,b,e   Kim, Tae You ^a,b,e  

^a Seoul National University Hospital   (South Korea)

^b Seoul National University   (South Korea)

^c National Cancer Center   (South Korea)

^d Sungkyunkwan University School of Medicine   (South Korea)

^e Seoul National University   (South Korea)

Author keywords

Breast cancer; Lapatinib; Transforming growth factor

Indexed keywords

CAPECITABINE; CETUXIMAB; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; TRANSFORMING GROWTH FACTOR ALPHA;

ADULT; AGED; ARTICLE; BLOOD LEVEL; BREAST CANCER; CANCER RESISTANCE; CANCER SURVIVAL; CHEMOSENSITIVITY; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; GENE OVEREXPRESSION; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PHARMACOGENETICS; PRIORITY JOURNAL; TRANSFORMING GROWTH FACTOR ALPHA BLOOD LEVEL;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CHI-SQUARE DISTRIBUTION; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUOROURACIL; HUMANS; KAPLAN-MEIER ESTIMATE; LOGISTIC MODELS; MIDDLE AGED; QUINAZOLINES; RECEPTOR, ERBB-2; REPUBLIC OF KOREA; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TRANSFORMING GROWTH FACTOR ALPHA; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 78651100870     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-010-1200-9     Document Type: Article

References (28)

1. DJ Slamon GM Clark SG Wong WJ Levin A Ullrich WL McGuire 1987 Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene Science 235 177 182 1:CAS:528:DyaL2sXhtVSht7s%3D 10.1126/science.3798106 3798106
2. DC Allred GM Clark AK Tandon R Molina DC Tormey CK Osborne KW Gilchrist EG Mansour M Abelofaf L Eudey, et al. 1992 HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma J Clin Oncol 10 599 605 1:STN:280:DyaK387ptl2ksg%3D%3D 1548522
3. WJ Gullick SB Love C Wright DM Barnes B Gusterson AL Harris DG Altman 1991 c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes Br J Cancer 63 434 438 1:STN:280:DyaK3M7mslWrsw%3D%3D 1672253
4. AH McCann PA Dervan M O'Regan MB Codd WJ Gullick BM Tobin DN Carney 1991 Prognostic significance of c-erbB-2 and estrogen receptor status in human breast cancer Cancer Res 51 3296 3303 1:STN:280:DyaK3M3kvFemtw%3D%3D 1674898
5. MJ Piccart-Gebhart M Procter B Leyland-Jones A Goldhirsch M Untch I Smith L Gianni J Baselga R Bell C Jackisch D Cameron M Dowsett CH Barrios G Steger CS Huang M Andersson M Inbar M Lichinitser I Lang U Nitz H Iwata C Thomssen C Lohrisch TM Suter J Ruschoff T Suto V Greatorex C Ward C Straehle E McFadden MS Dolci RD Gelber 2005 Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer N Engl J Med 353 1659 1672 1:CAS:528:DC%2BD2MXhtFansr3L 10.1056/NEJMoa052306 16236737 (Pubitemid 41464705)
6. I Smith M Procter RD Gelber S Guillaume A Feyereislova M Dowsett A Goldhirsch M Untch G Mariani J Baselga M Kaufmann D Cameron R Bell J Bergh R Coleman A Wardley N Harbeck RI Lopez P Mallmann K Gelmon N Wilcken E Wist P Sanchez Rovira MJ Piccart-Gebhart 2007 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial Lancet 369 29 36 1:CAS:528:DC%2BD2sXit12itg%3D%3D 10.1016/S0140-6736(07) 60028-2 17208639 (Pubitemid 46039831)
7. EH Romond EA Perez J Bryant VJ Suman CE Geyer Jr NE Davidson E Tan-Chiu S Martino S Paik PA Kaufman SM Swain TM Pisansky L Fehrenbacher LA Kutteh VG Vogel DW Visscher G Yothers RB Jenkins AM Brown SR Dakhil EP Mamounas WL Lingle PM Klein JN Ingle N Wolmark 2005 Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer N Engl J Med 353 1673 1684 1:CAS:528:DC%2BD2MXhtFansr3F 10.1056/NEJMoa052122 16236738 (Pubitemid 41464706)
8. DJ Slamon B Leyland-Jones S Shak H Fuchs V Paton A Bajamonde T Fleming W Eiermann J Wolter M Pegram J Baselga L Norton 2001 Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 N Engl J Med 344 783 792 1:CAS:528:DC%2BD3MXisVGktrc%3D 10.1056/NEJM200103153441101 11248153 (Pubitemid 32222155)
9. M Marty F Cognetti D Maraninchi R Snyder L Mauriac M Tubiana-Hulin S Chan D Grimes A Anton A Lluch J Kennedy K O'Byrne P Conte M Green C Ward K Mayne JM Extra 2005 Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group J Clin Oncol 23 4265 4274 1:CAS:528:DC%2BD2MXms12gs70%3D 10.1200/JCO.2005.04.173 15911866 (Pubitemid 46207001)
10. AD Seidman MN Fornier FJ Esteva L Tan S Kaptain A Bach KS Panageas C Arroyo V Valero V Currie T Gilewski M Theodoulou ME Moynahan M Moasser N Sklarin M Dickler G D'Andrea M Cristofanilli E Rivera GN Hortobagyi L Norton CA Hudis 2001 Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification J Clin Oncol 19 2587 2595 1:CAS:528:DC%2BD3MXkt1Omurk%3D 11352950
11. CE Geyer J Forster D Lindquist S Chan CG Romieu T Pienkowski A Jagiello-Gruszfeld J Crown A Chan B Kaufman D Skarlos M Campone N Davidson M Berger C Oliva SD Rubin S Stein D Cameron 2006 Lapatinib plus capecitabine for HER2-positive advanced breast cancer N Engl J Med 355 2733 2743 1:CAS:528:DC%2BD2sXhslSqsA%3D%3D 10.1056/NEJMoa064320 17192538 (Pubitemid 46021510)
12. W Xia RJ Mullin BR Keith LH Liu H Ma DW Rusnak G Owens KJ Alligood NL Spector 2002 Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways Oncogene 21 6255 6263 1:CAS:528:DC%2BD38Xms1yrs7w%3D 10.1038/sj.onc.1205794 12214266
13. DW Rusnak K Lackey K Affleck ER Wood KJ Alligood N Rhodes BR Keith DM Murray WB Knight RJ Mullin TM Gilmer 2001 The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo Mol Cancer Ther 1 85 94 1:CAS:528:DC%2BD38XlsFSmtbs%3D 12467226
14. GE Konecny MD Pegram N Venkatesan R Finn G Yang M Rahmeh M Untch DW Rusnak G Spehar RJ Mullin BR Keith TM Gilmer M Berger KC Podratz DJ Slamon 2006 Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells Cancer Res 66 1630 1639 1:CAS:528:DC%2BD28XpsVemsg%3D%3D 10.1158/0008-5472.CAN-05-1182 16452222 (Pubitemid 43259947)
15. Capri G, Chang J, Chen SC, Conte P, Cwiertka K, Jerusalem G, Jiang Z, Johnston S, Kaufman B, Link J, Ro J, Schütte J, Oliva C, Parikh R, Preston A, Rosenlund J, Selzer M, Zembryki D, De Placido S (2010) An open-label expanded access study of lapatinib and capecitabine in locally advanced or metastatic breast cancer. Ann Oncol 21:474-480
16. N Ishikawa Y Daigo A Takano M Taniwaki T Kato S Hayama H Murakami Y Takeshima K Inai H Nishimura E Tsuchiya N Kohno Y Nakamura 2005 Increases of amphiregulin and transforming growth factor-alpha in serum as predictors of poor response to gefitinib among patients with advanced non-small cell lung cancers Cancer Res 65 9176 9184 1:CAS:528:DC%2BD2MXhtFWmu77J 10.1158/0008-5472.CAN-05- 1556 16230376 (Pubitemid 41507981)
17. D Cameron M Casey M Press D Lindquist T Pienkowski CG Romieu S Chan A Jagiello-Gruszfeld B Kaufman J Crown A Chan M Campone P Viens N Davidson V Gorbounova JI Raats D Skarlos B Newstat D Roychowdhury P Paoletti C Oliva S Rubin S Stein CE Geyer 2008 A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyzes Breast Cancer Res Treat 112 533 543 1:CAS:528:DC%2BD1cXhtl2mu7bI 10.1007/s10549-007- 9885-0 18188694
18. M Toi H Iwata Y Fujiwara Y Ito S Nakamura Y Tokuda T Taguchi Y Rai K Aogi T Arai J Watanabe T Wakamatsu K Katsura CE Ellis RC Gagnon KE Allen Y Sasaki S Takashima 2009 Lapatinib monotherapy in patients with relapsed, advanced, or metastatic breast cancer: efficacy, safety, and biomarker results from Japanese patients phase II studies Br J Cancer 101 1676 1682 1:CAS:528:DC%2BD1MXhtl2hs7vE 10.1038/sj.bjc.6605343 19844234
19. P Therasse SG Arbuck EA Eisenhauer J Wanders RS Kaplan L Rubinstein J Verweij M Van Glabbeke AT van Oosterom MC Christian SG Gwyther 2000 New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 205 216 1:STN:280:DC%2BD3c7it1Gitg%3D%3D 10.1093/jnci/92.3.205 10655437
20. YK Yoon HP Kim SW Han HS Hur Y Oh do SA Im YJ Bang TY Kim 2009 Combination of EGFR and MEK1/2 inhibitor shows synergistic effects by suppressing EGFR/HER3-dependent AKT activation in human gastric cancer cells Mol Cancer Ther 8 2526 2536 1:CAS:528:DC%2BD1MXhtFCis7rJ 10.1158/1535-7163.MCT-09- 0300 19755509
21. HP Kim SW Han SH Kim SA Im DY Oh YJ Bang TY Kim 2008 Combined lapatinib and cetuximab enhance cytotoxicity against gefitinib-resistant lung cancer cells Mol Cancer Ther 7 607 615 1:CAS:528:DC%2BD1cXjtlWgsr8%3D 10.1158/1535-7163.MCT- 07-2068 18347147 (Pubitemid 351482143)
22. LM McShane DG Altman W Sauerbrei SE Taube M Gion GM Clark 2006 REporting recommendations for tumor MARKer prognostic studies (REMARK) Breast Cancer Res Treat 100 229 235 10.1007/s10549-006-9242-8 16932852 (Pubitemid 44631925)
23. NL Spector W Xia H Burris 3rd H Hurwitz EC Dees A Dowlati B O'Neil B Overmoyer PK Marcom KL Blackwell DA Smith KM Koch A Stead S Mangum MJ Ellis L Liu AK Man TM Bremer J Harris S Bacus 2005 Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies J Clin Oncol 23 2502 2512 1:CAS:528:DC%2BD2MXjvVyktLo%3D 10.1200/JCO.2005.12.157 15684311 (Pubitemid 47050840)
24. JK Mellon S Cook P Chambers DE Neal 1996 Transforming growth factor alpha and epidermal growth factor levels in bladder cancer and their relationship to epidermal growth factor receptor Br J Cancer 73 654 658 1:STN:280: DyaK287osVSnsg%3D%3D 8605103
25. WJ Muller CL Arteaga SK Muthuswamy PM Siegel MA Webster RD Cardiff KS Meise F Li SA Halter RJ Coffey 1996 Synergistic interaction of the Neu proto-oncogene product and transforming growth factor alpha in the mammary epithelium of transgenic mice Mol Cell Biol 16 5726 5736 1:CAS:528: DyaK28XlvFalsrw%3D 8816486
26. D Zhang A Pal WG Bornmann F Yamasaki FJ Esteva GN Hortobagyi C Bartholomeusz NT Ueno 2008 Activity of lapatinib is independent of EGFR expression level in HER2-overexpressing breast cancer cells Mol Cancer Ther 7 1846 1850 1:CAS:528:DC%2BD1cXoslCgtLc%3D 10.1158/1535-7163.MCT-08-0168 18644997
27. H Waterman I Sabanai B Geiger Y Yarden 1998 Alternative intracellular routing of ErbB receptors may determine signaling potency J Biol Chem 273 13819 13827 1:CAS:528:DyaK1cXjvVejurc%3D 10.1074/jbc.273.22.13819 9593726 (Pubitemid 28268432)
28. AR French DK Tadaki SK Niyogi DA Lauffenburger 1995 Intracellular trafficking of epidermal growth factor family ligands is directly influenced by the pH sensitivity of the receptor/ligand interaction J Biol Chem 270 4334 4340 1:CAS:528:DyaK2MXktFSitbk%3D 10.1074/jbc.270.9.4334 7876195